RDY logo

DR. REDDY'S LABORATORIES-ADR

RDYNYSE
🏆 #847 by market capEarnings Oct 22US Equity
$12.85▲ $0.35 (+2.72%)
🌙 After hours$12.85▲ 0.00%Regular close · extended-hours price shown
🔔
Track RDY
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.7%
7d▲ 2.2%
14d▲ 11.4%
30d▲ 5.5%
ytd▼ 8.5%
1y▼ 7.9%
🏦Market Cap
$10.70B
Mid Cap
📈Revenue Growth (YoY)
+8.6%
Slowing
📊Gross Margin
50.2%
Healthy
💵FCF Margin
4.4%
Moderate
⚖️P/S Ratio
3.1x
Fair
Otter Score
92
Very Good

Trading Snapshot

Day Range
$12.81 – $13.10
52-Week Range
$11.36 – $15.67
Volume
$2.32B
Avg Volume
$2.32B
Shares Outstanding
832.9M
Next Earnings
Nov 18, 2026

Fundamentals Snapshot

Annual Revenue
$353.47B
Last Q Revenue
$81.18B
P/E Ratio
31.5
P/S Ratio
3.1x
EPS (TTM)
$39.76
Dividend Yield
0.64%
Dilution (1yr)
−0.1%

Why Investors Own RDY

  • ✓High-growth profile — revenue up +30.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 54% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RDY logo

DR. REDDY'S LABORATORIES-ADR

RDY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$353.5B▲ +8.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
52.8%▼ −9.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$48.9B▼ −32.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$32.1B▲ +166.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
832.7M▼ −0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$60.7B▼ −$11.7B YoY
StockOtter · stockotter.space

About DR. REDDY'S LABORATORIES-ADR

Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
92/100

Analyst Ratings

ⓘ
Consensus
Hold
45 analysts
Strong Buy5
Buy9
Hold11
Sell14
Strong Sell6
Ratings as of Sep 2026

Latest News & Updates

PRNewsWire·5d ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).

Reuters·11d ago

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​for ​the promotion and ‌distribution ⁠of the Qdenga ​dengue ​vaccine ⁠in ​India.

GuruFocus·Aug 20

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf

Business Wire·Aug 20

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's”

GuruFocus·Aug 20

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: [url="]RDY[/url]

Business Wire·Aug 20

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible vio